trending Market Intelligence /marketintelligence/en/news-insights/trending/61RFq1iDwQyjuf4kJ0ttCw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: Bayer urges US appeals court to quash $25M Roundup decision

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Report: Bayer urges US appeals court to quash $25M Roundup decision

Bayer AG urged a U.S. federal appeals court to quash a verdict that ordered the company to pay $25 million to a man who alleged that his cancer was caused by the company's weedkiller Roundup, Reuters reported.

In March, a jury in San Francisco federal court ordered Bayer to pay $80 million to Edwin Hardeman who claimed that he developed non-Hodgkin lymphoma after using Roundup, which the German pharma and chemicals giant inherited following the $62.5 billion acquisition of Monsanto Co. in 2018.

The trial court judge slashed the $80 million verdict to $25 million in July.

Bayer said in a filing in the U.S. Court of Appeals for the 9th Circuit that the decision was contrary to regulatory findings. The company's arguments are centered on findings by the U.S. Environmental Protection Agency that glyphosate — the main ingredient in Roundup — is not a cancer-causing substance and not a risk to public health when used as per its label instructions, said the report.

The company is facing lawsuits from about 42,700 plaintiffs in the U.S. who allege that Roundup is responsible for causing cancer.